# Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis

> **NCT04507659** · PHASE2 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 108 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Jaktinib Hydrochloride Tablets
- **DRUG:** Jaktinib Hydrochloride Tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04507659
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2022-08-02
- **Final completion:** 2022-08-02
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04507659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04507659, "Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04507659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*